## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.02 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($346.65)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Top Superinvestors Are Buying Elevance Health (ELV)**
- Source: The Acquirer's Multiple | 20260105T224251 | Bullish | Relevance: 100%
- Several prominent investors, including Glenn Greenberg, Seth Klarman, Jeremy Grantham, and Cliff Asness, significantly increased their holdings in Elevance Health Inc. (ELV) this quarter. This broad-based accumulation signals strong confidence in the company's defensive characteristics, long-term earnings durability, and status as a high-quality healthcare compounder. The buying activity spans value, quantitative, and fundamental investors, reinforcing ELV's appeal across diverse investment strategies.

**2. Elevance Healthâ€™s Stock Holds Its Ground: Defensive Strength In A Market Searching For Direction**
- Source: AD HOC NEWS | 20260105T201816 | Bullish | Relevance: 100%
- Elevance Health's stock has shown consistent growth due to resilient earnings and disciplined capital returns, attracting a "Buy" consensus from Wall Street. Despite market fluctuations, the company's shares reflect a steady, almost stubborn resilience, making it a conviction pick for investors seeking earnings visibility and defensive cash flows. Its strategic shift into value-based care and services, alongside a strong standing in managed care, positions it well for future growth amidst regulatory scrutiny.

**3. Wellpoint Data Breach Exposes Protected Health Information (PHI)**
- Source: Claim Depot | 20260105T172804 | Somewhat-Bearish | Relevance: 100%
- Wellpoint, a health insurance provider affiliated with Elevance Health, reported a data breach to the U.S. Department of Health and Human Services on October 7, 2025. The incident involved unauthorized access to sensitive personally identifiable information (PII) and protected health information (PHI), potentially including names, Social Security numbers, medical records, and insurance details. Wellpoint has launched an investigation, secured its systems, and notified affected individuals, advising them to monitor their credit and insurance statements.

**4. LS Investment Advisors LLC Buys New Shares in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20260105T133212 | Bullish | Relevance: 100%
- LS Investment Advisors LLC has acquired a new stake of 3,150 shares in Elevance Health, Inc. (NYSE:ELV) during the third quarter, valued at approximately $1,018,000. Elevance Health exceeded Q3 earnings expectations and saw significant increases in institutional ownership from major firms such as Norges Bank, Sanders Capital, Vanguard, and The Manufacturers Life Insurance Company. Currently, institutional investors and hedge funds own 89.24% of the stock.

**5. Merit Financial Group LLC Increases Stock Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20260104T102110 | Bullish | Relevance: 100%
- Merit Financial Group LLC significantly increased its stake in Elevance Health, Inc. (NYSE:ELV) by 102.6% in the third quarter of 2025, bringing its total holdings to 6,972 shares valued at $2.253 million. This increase follows Elevance Health's strong Q3 performance, where it surpassed analyst expectations with $6.03 EPS and $50.09 billion in revenue. Institutional investors currently own 89.24% of the stock, which has a "Hold" consensus rating from analysts and a dividend yield of 1.9%.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $404 | $385 | +5% |
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | main | Overweight |
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Volume divergence: price rising (+3.2% MRS) on declining volume (64% of avg) suggests distribution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +3.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $81.9B |
| Beta | 0.52 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 13.5 |
| Current P/E | 12.1 |
| YoY Growth | -10.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 1.4% to 4.6% (+3.2% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 85th percentile. MRS_5 at 2.8% confirms short-term momentum alignment. AM_20 at 4.8% shows strong absolute momentum above own 20MA. Outperforming sector by 4.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.85), confirming momentum. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.59% (CS: 85) | Strong |
| RSI_14 | 67.8 | Neutral |
| MACD Histogram | 0.85 | Bullish |
| vs SMA20 | 1.048x | Above |
| vs SMA50 | 1.086x | Above |
| vs SMA200 | 1.030x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $363.57
- **Stop Loss:** $346.65 (4.7% risk)
- **Target:** $397.41 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $18,178.50
- **Portfolio %:** 18.18%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*